‘Enormous Burden' Cataloged in Relapsing Polychondritis
METHODOLOGY:
Researchers conducted a multicenter cohort study between 2017 and 2023 to evaluate clinical manifestations, treatment approaches, and the association between them in 195 patients with RP (median age, 48 years; 85.6% women).
A diagnosis of RP was confirmed using comprehensive laboratory, radiographic, and other tests; all participants tested negative for proteinase 3 and myeloperoxidase.
Data on clinical manifestations, organ damage, and medication history were collected at baseline study visits using standardized case report forms.
Patients were grouped by treatment: Group 1 received glucocorticoids or no drugs, group 2 received nonbiologic immunosuppressive drugs (excluding JAK inhibitors) with or without glucocorticoids, and group 3 received JAK inhibitors or biologic drugs with or without nonbiologic immunosuppressives or glucocorticoids.
TAKEAWAY:
All patients presented with at least three clinical manifestations of RP, with a median of 11 manifestations per patient; all showed ear, nose, or airway involvement, and 83% had musculoskeletal manifestations.
A substantial portion of patients (41%) developed organ damage, including sensorineural hearing loss (25%), auricular and saddle nose deformities (12% each), and subglottic stenosis (9%); among those who underwent dynamic CT of the chest, 31% had tracheomalacia, and 20% had bronchomalacia.
Treatment groups 1, 2, and 3 comprised 19%, 28%, and 53% of patients, respectively; most patients (95%) received glucocorticoids, and a substantial proportion (81%) received additional immunomodulatory treatments.
Patients in treatment group 3 had the highest rate of organ damage (62% vs 22% in group 2 and 15% in group 1) and were more likely to have arthritis and stenosis, whereas those in group 1 were less likely to experience nose pain.
IN PRACTICE:
'Standardized assessment of disease activity is warranted for patients with RP for early detection and timely initiation of treatment. These findings also highlight the absence of a consensus approach to treatment for patients with RP and underscore the need for clinical trials and treatment guidelines in this disease to help reduce the enormous burden of disease for patients,' the authors wrote.
SOURCE:
This study was led by Roger Yang, MD, University of Pennsylvania, Philadelphia, and University of Montreal, Montreal, Quebec, Canada. It was published online on May 20, 2025, in ACR Open Rheumatology .
LIMITATIONS:
This study did not capture data on dose and duration of immunomodulatory medications or clinical features at treatment decisions. Treatment choices were made independently by clinicians and may have been influenced by factors such as drug availability or insurance, introducing variability. Moreover, the academic referral setting may have contributed to selection bias.
DISCLOSURES:
Two authors reported receiving support from the Vasculitis Clinical Research Consortium, Association des médecins rhumatologues du Québec, Institute for Translational Medicine and Therapeutics, and other sources. This research was also supported by the Relapsing Polychondritis Foundation and other generous donors to the Penn Relapsing Polychondritis Program.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
26 minutes ago
- Yahoo
Mondayitis Could Have a Deadly Effect On Your Body
Don't like Mondays? You might be at higher risk of stress-related health problems, including cardiovascular disease. Modern society has built up Mondays to be the least-liked day of the week. We've just come back from a relaxing weekend and now have to face all the responsibilities we've been ignoring, knowing there's the longest possible time before another weekend. Not only did a recent study by researchers from the University of Hong Kong (HKU) identify a link between anxiety towards the first day of the working week and elevated levels of a stress hormone, the connection persisted even after retirement. While correlations do not equal causation, a jump in the stress signal cortisol is closely connected with risk of illnesses. Which could explain why a 2005 meta-analysis found that there's anywhere up to a 19 percent increase in cardiovascular events on Mondays compared to other days of the week. Related: In this latest study, researchers investigated a possible link between feelings of anxiety towards Mondays and physical health. The team examined 3,511 adults aged 50 years and over, taking part in the English Longitudinal Study of Aging (ELSA). Participants reported their levels of anxiety on different days of the week, while hair samples were also taken and analyzed for levels of the stress hormone cortisol. The study found that people who reported feeling particularly anxious on Mondays had cortisol levels around 23 percent higher than those who felt anxious on other days. This association seems to suggest that Monday anxiety affects the hypothalamic-pituitary-adrenal (HPA) axis, the body's main stress management system. But chronic stress can overstimulate the HPA axis and lead to immune system issues, metabolic diseases like cancer or diabetes, and cardiovascular disease. This could be the biological mechanism behind the earlier findings of increases in cardiovascular events on Mondays, suggests the team on the new study. It might seem like an obvious work-related hazard, but strangely the study found that even retirees still felt higher stress levels on Mondays, along with the negative health effects. "Mondays act as a cultural 'stress amplifier'," says Tarani Chandola, sociologist at HKU. "For some older adults, the week's transition triggers a biological cascade that lingers for months. This isn't about work – it's about how deeply ingrained Mondays are in our stress physiology, even after careers end." Maybe Garfield was onto something. The research was published in the Journal of Affective Disorders. Cannabis Use Is Linked to Epigenetic Changes, Scientists Discover To Tackle Our Obesity Crisis, Experts Say Everything We Do Must Change Big City Lights Could Be Damaging Your Heart Health
Yahoo
26 minutes ago
- Yahoo
One Piece of Advice to Parents Slashed Food Allergies in Children
New research highlights a crucial time window very early on in life, during which the introduction of eggs and peanut butter into the diets of babies significantly reduces the chances of them becoming allergic to these foods later on. The findings run counter to previous advice given to parents to avoid giving these foods to their kids until they're at least a year old over concerns that they might trigger allergic reactions. Here, researchers led by a team from the University of Western Australia compared the experiences of two groups of children in Australia: 506 whose parents got no specific feeding advice, and 566 whose parents were advised to start adding eggs and peanut butter to the diets of the infants at around six months. Related: "For the babies in group two – whose caregivers followed the updated guidelines and introduced peanut butter and egg around six months of age – egg allergy reduced from 12 percent to 3 percent, and peanut allergy reduced from around 6 percent to 1 percent," says Summer Walker, a health scientist at the University of Western Australia. In other words, earlier introduction of these foods at the six-month mark made a notable difference to the number of kids who went on to develop allergies by 12 months of age. Cow's milk was also included, though here the difference was smaller. The advice itself isn't new, and the six-month milestone has in fact now been added to the official Infant Feeding and Allergy Prevention Guidelines proposed by the Australasian Society of Clinical Immunology and Allergy (ASCIA). Testing the guidelines in real population groups confirms the recommendations are safe and effective. The parents of the second group of 566 were provided with hard copies of the ASCIA guidelines, and the researchers are keen to raise awareness of the latest expert advice on how best to reduce allergy risk. "By increasing the distribution of guidelines and encouraging health professionals to share the information, we can considerably reduce the incidence of food allergies in the community," says Walker. Understanding why allergies develop is a complex challenge, and it's important to note that these infants were only tested for allergies up to 12 months – and that allergies to peanut butter and eggs weren't completely eradicated. Nonetheless, amid signs that food allergies in children have been on the rise in spite of instructions to avoid specific food items, a review of the relationship between diet and immune responses is critical. This is just one part of the picture, but it's strong evidence that the latest guidelines do make a difference – even in relation to a higher level of genetic risk. All the babies involved in the research had a close relative with an allergy to one of these foods, and allergies often run in families. "Some parents are still confused about when to introduce allergens – especially those families with a history of allergies," says research dietitian Debbie Palmer, from the University of Western Australia. The research has been published in the Journal of Allergy and Clinical Immunology: In Practice. Mondayitis Could Have a Deadly Effect On Your Body Cannabis Use Is Linked to Epigenetic Changes, Scientists Discover To Tackle Our Obesity Crisis, Experts Say Everything We Do Must Change
Yahoo
27 minutes ago
- Yahoo
Scientists Gene Hack Mice So Their Livers Produce Their Own Ozempic-Like Drug
Scientists have gene-hacked mice to produce their own Ozempic-like drugs — possibly, and provocatively, perhaps paving a path for humans to do so themselves one day. In a new study published in the journal Communications Medicine, researchers from Japan's University of Osaka successfully gene-edited mice livers to produce exenatide, a first-generation diabetes drug and predecessor to now-trendy jabs like Ozempic and Mounjaro. Using lab mice that were obese and pre-diabetic — which sounds, we have to note, both sad and adorable — the researchers used a CRISPR-based genetic editing method to add a gene to the rodents' liver cells instructing them how make exenatide. Soon after, the Osaka researchers detected the drug in the rodents' blood, and kept finding it for up to 28 weeks as the gene-edited mice "ate less food and gained less weight" than their unedited counterparts, as a press release about the study explains. It's not the first time researchers have gene-hacked living things into creating glucagon-like peptide-1 (GLP-1) receptor/agonists, the class of drugs to which Ozempic belongs, and which are believed to mimic the stomach's feeling of fullness. Back in 2017, researchers from the University of Chicago gene-edited human and mice skin cells to produce GLP-1, then grafted them onto host animals that subsequently showed increased insulin secretion and reversed weight gain. And more recently, student scientists at Canada's University of Ottawa genetically tricked a tobacco cousin into producing a similar compound. Taken all together, and it's an intriguing proof of concept for bespoke genetic treatments that could help the body produce its own medication — a radical departure from the current model of the pharmaceutical and medical industries. "We hope that our design of a one-time genetic treatment can be applied to many conditions that do not have exact genetic causes," explained Keiichiro Suzuki, the study's senior author, in the press release. Still, as Gizmodo notes, not all GLP-1s are created equal. Taken twice a day orally, the original formula of exenatide made it far less long-lasting than semaglutide, and although an extended-release version was eventually manufactured and sold, both have since been discontinued over long-known risks of pancreatitis — though to be fair, Ozempic has been linked to the same condition, even if the research remains inconclusive. While it remains unclear whether the Osaka researchers plan to experiment with a compound closer to semaglutide, the biopharmaceutical company Fractyl Health has also been working on a gene therapy that trains the body to create its own GLP-1s. Earlier this year, the company began the approval process for human trials in Europe, which will begin next year if accepted by health regulators. Notably, neither of these mice studies addressed the GLP-1 elephant in the room: that these drugs, regardless of exact formulation, carry an increased risk of pancreatitis and other gastrointestinal problems. Could producing them in-vivo result in fewer side effects? It seems too early to tell — but we'll be watching. More on GLP-1 research: Human Experiments on GLP-1 Pill Looking Extremely Promising
